Kennedy, Jr. as head of Health and Human Services may well be the political price he is forced to pay for an alliance that ...

The rise in cardiovascular disease prevalence, aging populations, and technological advancements in the field drive increased demand for interventional cardiology devices. As the industry prepares for ...

Compared with a contemporary zotarolimus drug-eluting stent, a coronary bioadaptor system is noninferior among patients with CAD receiving PCI.

Robert L. Minor Jr, MD Interventional Cardiologist and Endovascular Specialist Director of Endovascular Interventions Limb ...

The global Implantable Drug Eluting Devices Market is poised for substantial growth, projected to expand at a compound annual growth rate (CAGR) of 6.0% from 2022 to 2029. The market, valued at ...

The company is one of the leading players in the interventional cardiology market with its coronary stent product offerings. Boston Scientific markets a broad portfolio of internally-developed and ...

Solaris Endovascular, Inc. recently announced the formation of the company, which will develop solutions for dialysis access i ...

The following is a summary of “Evaluation of Small Vessel Bifurcation Stenting Using the Double-Kissing Culotte and Culotte ...

PORTLAND, GA, UNITED STATES, November 20, 2024 /EINPresswire / -- The global angioplasty balloons market size was valued at $2.6 billion in 2023, and is projected to reach $3.6 billion by 2033, ...

Findings seen for individuals undergoing revascularization after non-ST-segment elevation myocardial infarction ...

Future Cardiol. 2009;5(2):141-157. Safety data for complex lesions with PES use led to the double-blind, multicenter TAXUS VI study. [33] This study included 444 patients with long and complex ...

At the same time, metal-free percutaneous coronary intervention (PCI) and Drug-Eluting Balloons (DEB) present new possibilities for treating complex lesions without leaving permanent stents behind.